Oxford Drug Design Board of Directors announces the appointment of Dr. Alan D. Roth Chief Executive Officer, effective immediately.

Alan takes over the position from Dr. Paul W. Finn, who will remain with the company as Chief Scientific Officer.

Alan’s career in health sciences comprises executive operations, academic research, investment management/capital markets and strategic consultancy. He started his career at Merck & Co. in New Lead Discovery, before moving into consultancy at McKinsey serving leading companies globally. He was Director at Commerzbank Asset Management in charge of global healthcare investments and industrial investment research. He co-founded, took public and was the first CEO and CFO of Chiral Quest, a life sciences company in the area of chiral pharmaceuticals. He is also currently Director at Fitzroy Partners in London developing new life sciences ventures.

Dr. Finn said, “Oxford Drug Design’s unique combination of computational drug design technology and therapeutic pipeline is progressing rapidly.  Alan brings key knowledge and expertise that will be instrumental to the company’s growth and development.  I am greatly looking forward to working with Alan to take Oxford Drug Design to the next level”.

Dr. Roth said “I am delighted to be joining the team at Oxford Drug Design and look forward to building further on the significant achievements made thus far. In our next stage of development ODD can deliver important impact across selected therapeutic and the related computational areas”

Alan earned his BA (Hons) from Cornell University, PhD in organic chemistry from Columbia University and Postdoctoral Fellowship in medicinal chemistry from the University of Oxford. He is Royal Society Entrepreneur in Residence and Visiting Lecturer at Oxford in science entrepreneurship.